Ovarian Cancer Clinical Trial
Official title:
Testing a Low Cost Population- and Theory-Based Outreach Intervention to Engage Ovarian Cancer Survivors and Their Close Relatives to Consider Genetic Services
Verified date | February 2024 |
Source | Emory University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study tests a multi-component, low cost, message-based communication outreach intervention to engage ovarian cancer survivors and their at-risk relatives in considering cancer genetic services. The intervention includes foot-in-the-door techniques, tailored/targeted print, website support, and short messages to expand reach of prevention messages.
Status | Completed |
Enrollment | 349 |
Est. completion date | February 21, 2023 |
Est. primary completion date | February 21, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria for Survivors: - in the Georgia Cancer Registry (GSR) - diagnosed with ovarian, fallopian tube, or peritoneal cancers - lived in Georgia at the time of diagnosis - not deceased per the registry's records - have a mailing address in GSR records Inclusion Criteria for Close Relatives: - 25 years or older - able to access the internet - a 1st or 2nd degree relative of the survivor - able to read English - non-incarcerated or institutionalized Exclusion Criteria: - none |
Country | Name | City | State |
---|---|---|---|
United States | Emory University | Atlanta | Georgia |
Lead Sponsor | Collaborator |
---|---|
Emory University | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of Survivors Accessing the Website | Survivor reach is assessed as the proportion of the eligible survivors identified and contacted by GCR who log in to the website. | Up to 31 months | |
Primary | Proportion of Relatives of Survivors Accessing the Website | Close relative reach is assessed as the proportion of close relatives enumerated by survivors who log in to the website. | Up to 31 months | |
Primary | Proportion of Survivors Completing Telegenetic Counseling | Uptake of cancer genetic services will be assessed as the proportion of untested survivors who complete telegenetic counseling. | Up to 31 months | |
Primary | Proportion of Relatives Completing Telegenetic Counseling | Uptake of cancer genetic services by relatives of survivors will be assessed as the proportion of relatives enumerated who complete the Breast Cancer Genetics Referral Screening Tool (B-RST) screening and subsequently access genetic counseling. | Up to 31 months | |
Secondary | Time Visiting Website by Survivors | Among those in the intervention arm, the duration of time (in minutes) that survivors spend on the website will be examined. | Up to 31 months | |
Secondary | Time Visiting Website by Relatives | Among those in the intervention arm, the duration of time (in minutes) that relatives of survivors spend on the website will be examined. | Up to 31 months | |
Secondary | Number of Return Visits to Website by Survivors | Among those in the intervention arm, the number of return visits to the website by survivors will be examined. | Up to 31 months | |
Secondary | Number of Return Visits to Website by Relatives | Among those in the intervention arm, the number of return visits to the website by relatives of survivors will be examined. | Up to 31 months | |
Secondary | Number of Pages Viewed by Survivors | Among those in the intervention arm, the number of website pages viewed by survivors will be examined. | Up to 31 months | |
Secondary | Number of Pages Viewed by Relatives | Among those in the intervention arm, the number of website pages viewed by relatives of survivors will be examined. | Up to 31 months | |
Secondary | Proportion Selecting Contact Options | The proportion of survivors in the intervention arm who select different relative contact options will be examined. | Up to 31 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Withdrawn |
NCT05201001 -
APX005M in Patients With Recurrent Ovarian Cancer
|
Phase 2 | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05156892 -
Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer
|
Phase 1 | |
Suspended |
NCT02432378 -
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
|
Phase 1/Phase 2 | |
Recruiting |
NCT04533763 -
Living WELL: A Web-Based Program for Ovarian Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT03371693 -
Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer
|
Phase 3 | |
Withdrawn |
NCT03032614 -
Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients
|
Phase 2 | |
Completed |
NCT02019524 -
Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients
|
Phase 1 | |
Completed |
NCT01936363 -
Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer
|
Phase 2 | |
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05059522 -
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
|
Phase 3 | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Terminated |
NCT04586335 -
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
|
Phase 1 | |
Terminated |
NCT03146663 -
NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer
|
Phase 2 |